Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cell Death and Differentiation|September 30, 2024
Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathwayRita A Avelar, Riya Gupta, Grace Carvette, et al.
Cancer Research|December 18, 2021
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous CarcinomaCaitlin M O'Connor, Sarah E Taylor, Kathryn M Miller, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
The SRG RAT® supports human cell xenotransplantation through enhanced tumor microenvironment interactionsCaitlin M O'Connor, Kaitlin P Zawacki, Jessica R Durrant, et al.
JCI Insight|April 3, 2025
Germline mutations in PPP2R1B in patients with a personal and family history of cancerSahar Mazhar, Caitlin M O'Connor, Alexis Harold, et al.
Science Translational Medicine|July 20, 2018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cellsOtto Kauko, Caitlin M O'Connor, Evgeny Kulesskiy, et al.
The Journal of Clinical Investigation|January 27, 2025
Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cellsMichelle A Lum, Kayla A Jonas, Shreya Parmar, et al.
The Journal of Clinical Investigation|May 11, 2023
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosisKallesh D Jayappa, Brian Tran, Vicki L Gordon, et al.
Oncogene|September 22, 2019
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitorsCaitlin M O'Connor, Daniel Leonard, Danica Wiredja, et al.
The Journal of Clinical Investigation|October 14, 2025
A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancerBrynne Raines, Stephanie Tseng-Rogenski, Amanda C Dowdican, et al.
Pageof 3